Is it true that the Chinese trade name for Sofosbuvir/Vipatasvir combination tablets is "丙统杀"? Whoever came up with that name wasn't "Benji", was he? --Hepatitis C virus, you guys. All of you. Dead and dying. 。。。。 😎😎😎😎😎😎

However, I'm afraid that the name "Gizumab" is more widely known than Protonixa. Many Chinese liver doctors and even well-known experts may not be able to call "sof/vel" the full name of the drug in English, abbreviation or any one of the Chinese name, and can only follow the Indian generic drug traffickers to call it a "Jisandai" it. 😓😓😓😓😓😓😓😓

For a variety of reasons, Indian generic small molecule oral antiviral drugs for Hepatitis C have become a household name among hepatologists and the Hepatitis C patient community (the title image for this question is the 🐔2nd and 🐔3rd generation Indian generics ahah 😂), and they work well too. This makes the market share of multiple new Hepatitis C drugs just launched in China extremely low.

At first, the drug companies thought they couldn't beat the Indian generics because they couldn't do full genotype coverage, I guess. But this time the sofosbuvir/viplatasvir combination tablets (propecia) is really a genotype of a piece of the child to kill. Can it unify the world and expel the smuggled drugs? I don't think so.

The unit price of sofosbuvir in China is now 19,660 yuan per month, totaling 58,980 yuan for a three-month course. The price of this propecia can't be cheaper than the single drug, even if it's equal, it will cost 60,000 per person to cure Hepatitis C. This price is 5-10 times that of the Indian generic drug (the price asked by drug dealers varies). Even if the future health insurance coverage, will not be reimbursed much ah - take the Beijing health insurance, outpatient reimbursement is capped at 20,000 yuan per year. This disease can be cured with medication, and does not require hospitalization, which means that even in the best health insurance conditions in Beijing, to take this medication themselves will have to spend more than 40,000 。。。。

In addition, many domestic drug companies are about to launch similar drugs, and then there will be even more competitors.

So the biggest failure of Gilead and now all the new Hepatitis C drug makers in the Chinese market is even if they don't consider Indian generics when pricing. Actually, the new Hepatitis B drug, tenofovir, has already taught them that lesson. When tenofovir was first launched in China, it cost 1,470 yuan per month, while the Indian generic was only about 500 yuan. So GSK couldn't fuck with the Indian generic. Then the Chinese government led a price cut to $490/month, plus health insurance coverage, which made the Indian generic tenofovir almost roll off.

Now that it is the turn of Hepatitis C drugs, why are the heads of the marketing departments of these multinational corporations still unable to turn their heads? Do they still have to rely on the Chinese government to guide them administratively? 😄😄😄😄

There are currently six oral hepatitis C medications that have been officially approved for marketing in China, namely, Schweppes' Balize (dalatasvir hydrochloride tablets) and Speed (asurevir soft gelatin capsules); Gilead's Sofaldi (sofosbuvir tablets) and Gizandi's Propecia; and AbbVie's Ezire (daclatasvir sodium tablets).

They have different characteristics, for example, dalatasvir hydrochloride tablets are indicated for the treatment of chronic hepatitis C virus infection in adults. It needs to be combined with other medications and dalatasvir hydrochloride tablets should not be used as monotherapy. Here are its recommended dosages. Daratavir hydrochloride tablets in combination with Sovaldi is the only regimen recommended by the 15-year guidelines that can cover the full genotype. Asurevir soft capsules, in combination with dalatasvir hydrochloride tablets, are used to treat adults with genotype 1b chronic hepatitis C (non-cirrhotic or compensated cirrhosis); sofosbuvir tablets are suitable for use in combination with other medicines for the treatment of chronic hepatitis C virus infection in adults and adolescents 12 to less than 18 years of age. Both dasabuvir sodium tablets and obiparib tablets are needed in combination with other medicines to treat chronic hepatitis C in adults. "Genisys" propecia is the most expensive and the only newly approved monotherapy drug that covers the entire genotype regimen and has been made a miracle drug by hepatitis C patients. Gizumab has long been marketed in India, and there are many websites online that claim to be able to purchase it on behalf of the patient, at a price much lower than the domestic price, but ordering treatment online cannot be guaranteed, and there have been a lot of problems with the treatment. And there are many subtypes of hepatitis C. Other kinds of drugs also have good efficacy for genotypes within the indications and are relatively inexpensive. The country has included propecia in the essential medicines list, which will reduce the burden on patients. Therefore, from a safety point of view, you should purchase drugs through regular channels and listen to more professional advice in choosing drugs.

The authoritative interpretation of Pharmaceutical Affairs, unauthorized reproduction, plagiarism will be punished.

I consulted the Indian Guggisan generation a course of treatment for 3 months is also about 15,000, and the price of domestic drugs if far more than India slightly higher, if a little higher, the country would rather use their own production is not used in India, if the price is much higher it is not good to say, after all, these patients due to the treatment of the disease before spending a lot of money, money is very important to them, the rich or the price of the people do not care about the people is after all a small number of people, expect the We hope that the domestic drugs can be accepted by the patients.

Gilead launched Giselle in August 2016, and since then Hepatitis C has begun an era of cure, with a complete cure in just three boxes, regardless of genotyping and other differences.

The world's first generic drug from Bicom Bangladesh was launched right after the genuine version, later joined by India's two manufacturing giants mylan and natco, and the price went completely into the common man's era.

Domestic genuine Gisan generation named propecia, listed in 2018, than the United States a full three years later, the total cost of honestly as always, not grounded, there are always people asking when to enter the medical insurance, can the condition still wait to enter the medical insurance?

As a standard therapy, both generic companies, Bicom and India, are regular manufacturers, and there is no difference in efficacy as long as the quality is guaranteed when purchased through regular channels.

As you can see from the chart below, from previous use, all but one patient who was also infected with the HIV virus did not achieve conversion.